Device developer Cambridge Healthcare Innovations (CHI) has announced the appointment of former AuroScience Head of Device Development Philip Canner as CEO. In addition to AuroScience, an Aurobindo subsidiary that develops generic inhaled drugs, Canner’s OINDP development experience also includes a stint at Team Consulting.
Earlier this year, CHI partnered with Kindeva Drug Delivery on development and commercialization of CHI’s Aeolus DPI. The company is also developing an inhaler monitoring system called “q-technology.”
CHI co-founder and Chief Technology Officer David Harris, CTO commented, “We are excited to welcome Philip as the CEO of CHI. Philip brings expertise in leading device development programs from the proof-of-science stage, and his management, commercial and organizational behavior and change experience are ideal for CHI as we grow. Coupled with his leadership, Philip’s mechanical engineering and dry powder inhaler expertise continues to bolster our technical strength. I look forward to working with Philip as we develop our novel dry powder inhaler technology, aeolus, and as we continue to innovate into the future to improve patients’ lives.”
Canner said, “I am delighted to have accepted the role of CEO of CHI at this exciting time in its journey. I look forward to working with the team to develop and commercialize aeolus, and to build and drive the company to meet its strategic objectives. Having worked on several DPI technologies, I can see that the aeolus technology is a truly novel and exciting DPI platform. I look forward to helping CHI succeed with aeolus and all its future innovative technologies that the incredible team will deliver.”
Read the Cambridge Healthcare Innovations press release.
